OptimizeRx Corporation (OPRX) Earnings Call Transcript
November 11, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thanks for being with us on OptimizeRx's earnings conference call for the third quarter of fiscal 2026. Our Chief Executive Officer, Stephen Silvestro, is here today. With him are Edward Stelmakh, our Chief Financial and Strategy Officer; Marion Oden Ford, Chief Legal and Administrative Officer; Andy DeSilva, Chief Business Officer; and Heather Fava, Corporate Controller. Once the call wraps up, I'll go over a few important items regarding forward-looking statements that management has made today. The company will also cover certain non-GAAP financial measures that it considers helpful in assessing operating performance, and you can find a reconciliation of those non-GAAP financial measures in today's earnings release and in the investor relations section of the company's website. Before we begin, please note that this call is being recorded and a replay will be posted in the investor relations section of the company's website. I'll now hand things over to Stephen Silvestro, Chief Executive Officer of OptimizeRx. Thanks, operator, and good afternoon, everyone. We appreciate you joining us for our third quarter 2026 earnings call. We're happy to share that third quarter revenue reached $21.6 million, with adjusted EBITDA of $6.3 million — both figures above consensus expectations. Revenue was slightly better than anticipated, while our adjusted EBITDA result stood out as especially strong, driven by sustained gross margin strength and the gains from our disciplined cost management approach. Our earnings at the bottom line, in large part, show the structural changes we've implemented in how we run the business — this includes the cost-cutting program that wrapped up in the first half of the year. Thanks to these steps, we're running more efficiently and still putting money into the technologies, products, and commercial capabilities that we expect to fuel growth over the long term. The pharmaceutical marketing landscape as a whole is still changing, but we think the third quarter results show the profitability and operating leverage that sit beneath our business. That said, we're aware that our top line has yet to capture everything the investments in our platform could deliver. Contracted revenue for 2026 is still running about 20% under the prior-year comparison. Because of that, we now need to lock in and recognize a bigger chunk of revenue in Q4 to hit the guidance we put out earlier. With that in mind, we're revising our full-year '26 revenue outlook to $87 million to $93 million, and we're keeping adjusted EBITDA guidance at $21 million to $25 million. This revision takes into account when we now expect our customers to make their spending decisions, along with the larger volume of business that would have to convert and be recognized before year-end for us to hit the revenue expectations we previously set; we continue to feel encouraged by the sustainable progress being made throughout our business, including a very encouraging start to 2027; we are seeing expanded opportunities within key accounts, signs of pent-up demand as customers ramp up the 2027 RFP season, and growing commercial opportunities tied to our programmatic distribution capabilities. We're also happy to share that a top 5 client that had previously been displaced has come back and started investing again in new solutions with OptimizeRx. As you might remember, this customer accounted for a meaningful share of our revenue in 2025, yet produced no revenue across the first 3 quarters of 2026; we're pleased to say now that revenue from this customer started coming in during the fourth quarter. Spending hasn't yet gone back to historical levels, but we see this as a positive step and an encouraging sign of renewed engagement and interest from the customer, and of its contribution to growth next year in 2027. Beyond that, we're encouraged by how far we've come in strengthening our commercial organization. During Q3, Sarah Bass joined OptimizeRx in the Chief Marketing Officer role. She brings over 20 years of experience in pharmaceutical marketing, including notable leadership positions in point-of-care media and agency partnerships. Bringing her aboard represents a meaningful investment in advancing our mission and go-to-market strategy as we strive to build deeper ties with pharmaceutical manufacturers, reinforce our position with top healthcare marketing agencies, and accelerate uptake of our growing product portfolio. Equally important, we see our updated outlook as reflecting near-term timing and conversion of customer spending, not any shift in our long-term market opportunity. We remain focused on turning those opportunities into revenue, and on maintaining the financial discipline and operational efficiency behind our strong profitability and performance. Ted will soon provide more detail on our financial results and outlook. As for the wider market, drugmakers continue to operate in conditions defined by shifting spending priorities, tighter budgets, and greater emphasis on demonstrable returns from marketing investment. Those forces have played a part in postponing some customer decisions and affecting when campaigns are carried out, yet feedback about demand for our solutions remains encouraging. One key point to note is that OptimizeRx stands apart as the sole technology firm in this sector possessing a proven AI-powered operating system that is quickly expanding information throughout a proprietary network of EHR systems. Such interactions rest on OptimizeRx's expanding proprietary data, and that data lets our technology locate patients who need therapy along with the physicians treating them. When we talk with our pharma and agency customers, we keep seeing strong interest in solutions that sharpen targeting precision, produce measurable outcomes, and connect with healthcare providers and patients right when engagement matters most. Our priority continues to be converting that interest into signed agreements, active campaigns, and recognized revenue. We think our customer base has pent-up demand, since pharmaceutical manufacturers are weighing how and when to put their remaining marketing budgets to work. Forecasting the timing of that spending is still difficult, but the underlying customer needs match up well with what we have built across the platform. We believe that combining stronger commercial leadership with the broader distribution reach that comes from our programmatic efforts will improve our ability to capture demand as customer spending is expected to normalize in 2027. Our technology is designed to anticipate future treatment eligibility and to help pharmaceutical manufacturers reach the right audiences at critical moments in the patient journey, rather than relying solely on historical patient characteristics or static audience definitions. We view this method as a substantial leap forward in the way life sciences companies locate and connect with prospective treatment candidates; in our opinion, these proprietary and patented capabilities will become increasingly valuable as drugmakers seek more advanced, measurable, and AI-driven approaches to commercial engagement. We continue to achieve strong progress on our programmatic strategy, which we regard as 1 of OptimizeRx's most important long-term growth possibilities. Since we made our proprietary EHR network available for programmatic purchasing earlier this year, we have established relationships with 3 top demand-side platforms: DeepIntent, The Trade Desk, and most recently, PulsePoint. These integrations let pharmaceutical manufacturers and agencies reach our authenticated point-of-care inventory through the very platforms they already depend on for planning and running campaigns. In September we unveiled a tie-up with The Trade Desk via its Open Path offering, which opens up more than 800,000 verified healthcare professionals, spanning over 400 EHR and e-prescribing systems in OptimizeRx's point-of-care network, to advertisers.
Just recently, we shared news of a partnership with PulsePoint, which widens our programmatic distribution reach even further. Thanks to this integration, OptimizeRx is going to add roughly 250,000 incremental NPIs into PulsePoint's network. Our inventory should become available to advertisers on PulsePoint at some point during November. What matters is that these partnerships amount to far more than extra distribution channels. They mark a significant move toward weaving point-of-care advertising into the wider omni-channel strategies that pharmaceutical marketers pursue. In the past, EHR advertising was mostly bought via direct relationships or through specialized channels, frequently apart from other digital investments. Our programmatic approach is built to remove those obstacles, so customers find it simpler to fold authenticated clinical inventory into the media plans they already run. By widening access across multiple leading DSPs, we are opening up fresh opportunities to reach advertisers, boost utilization of our proprietary network, and capture a larger portion of pharmaceutical marketing budgets. Although these initiatives are still in the early stages of commercialization, we see them as a meaningful evolution in our business model. Instead of depending solely on traditional direct sales, we are constructing a more scalable distribution infrastructure that lets demand flow into our network via multiple channels. Our differentiated AI-enabled audience intelligence plus authenticated clinical inventory, combined with this strategy, should let OptimizeRx benefit from the continuing move toward programmatic healthcare advertising, and it creates further chances for durable revenue growth over the long term. We likewise continued growing our portfolio of AI-enabled products. In September we unveiled an upgrade to our Natural Language Audience Builder, NLAB, which takes its capabilities past healthcare provider audiences and adds privacy-safe direct-to-consumer audiences. With our micro-neighborhood targeting capabilities now incorporated, NLAB enables pharmaceutical marketers and agencies to construct coordinated HCP and consumer audiences through one unified natural language workflow. This represents a significant step forward in our effort to make omni-channel healthcare marketing simpler. Rather than building HCP and DTC campaigns via separate planning workflows, marketers are able to apply one shared method for identifying and activating the right audiences in both channels. In our view, that boosts planning efficiency, tightens audience coordination, and opens up chances for engagement that is both more effective and more efficient throughout the patient treatment journey. Together with DAP, our programmatic integrations, and CoPayQ, which we launched recently, these capabilities are expanding the options pharmaceutical manufacturers have for reaching healthcare professionals and patients on our platform. Considered as a whole, these efforts show how we have moved beyond a traditional point-of-care marketing business to become a wider technology-enabled industry platform that supports audience intelligence, media planning, programmatic activation, and clinical workflow engagement. As time goes on, we think this shift could open up more chances for recurring revenue, boost how well we keep customers, and make our financial model more scalable. Going forward, I think OptimizeRx is distinctive thanks to three core competitive strengths. To start, we've developed a platform powered by AI that's proven and scales better and better. For years, AI has been central to how we approach technology. And offerings like DAP and NLAB show how we turn that investment into commercial capabilities that set us apart. Crucially, we think our platform can handle more customers and use cases without our cost structure rising in proportion. And second, in a landscape increasingly shaped by AI, our proprietary data and solutions provide genuine differentiation. Sure — while general-purpose AI might handle a lot of marketing tasks, replicating or disintermediating our offering would be tough, in our view. What we provide combines proprietary healthcare data, predictive intelligence, and authenticated access to clinical workflows. Third, we've created a proprietary network that reaches a large audience and has meaningful barriers to entry. Thanks to integrations with over 450 EHR and e-prescribing systems, we can reach more than 1.1 million verified healthcare professionals. Those relationships and technical integrations took years to build, and they provide us with a durable competitive advantage. Taken together, these core competitive strengths leave OptimizeRx well positioned to gain from healthcare marketing's continued shift toward AI-enabled planning, programmatic activation, and engagement that can be measured. As 2026 draws to a close and we start getting ready for 2027, our priorities are unchanged. First, we're concentrating on better top-line execution and on converting the commercial opportunities that are in our pipeline right now. Second, we'll keep widening adoption of our AI-enabled, data-driven technologies, DAP and NLAB among them, while building on our proprietary data asset and our expanding portfolio of intellectual property. Third, we'll work on driving greater utilization of our proprietary network via programmatic distribution and further strategic partnerships. Finally, we remain dedicated to the fiscal rigor and operational efficiency that have supported our robust profitability results. In our view, these priorities combined mean OptimizeRx is set to emerge from this current period of spending uncertainty with an improved operating model, wider technology capabilities, and additional paths toward sustainable growth. Before turning the call over to Ed, I also want to speak about the finance leadership change we made public earlier. This is Ed's last earnings call with OptimizeRx as of today, although he will continue in his role as Chief Financial and Strategy Officer until the close of 2026. Effective January 1, 2027, Andy DeSilva is set to assume the Chief Financial Officer position, while Heather Favazza will step into the Chief Accounting Officer role; that handover remains on schedule, and we appreciate Ed's ongoing guidance and backing as we prepare for OptimizeRx's upcoming growth chapter. On a personal note, I want to express my gratitude to Ed for the remarkable leadership he has demonstrated throughout his tenure here at OptimizeRx; with that said, let's hand the time over to Ed.
Thanks, Steve, and good afternoon to everyone. We released our earnings this afternoon, as usual, laying out the financial results for the third quarter that closed on September 30, 2026. You can find a copy of that release in the investor relations section of our website, and more detail will be included in our upcoming Form 10-Q. Revenue for the third quarter came in at $21.6 million, which is down 17% from the $26.1 million we recognized in the same period of 2025. Compared with the same period last year, the drop came primarily from reduced spending by a small group of major customers—among them clients who had previously used our managed services offering, which carries thinner margins—as well as ongoing budget constraints and postponed spending related to wider market conditions, including uncertainty around MFN pricing. For the quarter that closed on September 30, 2026, expenses declined by $5.1 million versus the prior year to $18.9 million, reflecting a decrease in cost of revenue and compensation-related costs, despite a $0.7 million hit from severance charges associated with the workforce reduction we announced earlier. The decline in cost of revenue stemmed mainly from a favorable mix of products and channels, which included a sizable cut in revenue from DTC managed services during the quarter. Margin optimization efforts we have been running for the past 18 months continue to produce substantial gains, and those efforts yield anticipated gross margins in the low 70% range for all of 2026. Third-quarter 2026 net income came to $1.2 million, equal to $0.06 per basic and diluted share, compared with $0.8 million, or $0.04 per basic and diluted share, in the third quarter of 2025. Non-GAAP net income for the third quarter of 2026 totaled $3.8 million, or $0.20 per diluted share. For comparison, the year-earlier figure was $3.1 million, equal to $0.16 per diluted share. In the third quarter of 2026, adjusted EBITDA came to $6.3 million, versus $5.1 million in the third quarter of 2025. Although revenue fell 17% during the third quarter of 2026, our adjusted EBITDA margin reached roughly 29% for that quarter, compared with approximately 20% in the third quarter of 2025 — an improvement exceeding 900 basis points. In our view, this demonstrates that our margin optimization and cost management initiatives are producing results, and that our business model is capable of generating greater profitability as revenue increases. During the opening three quarters of 2026, cash generated by operations came to $12.9 million, and we closed the quarter holding $22.3 million in cash, versus $23.4 million as of December 31, 2025. As we mentioned a quarter ago, we refinanced our long-term loan with Blue Source Capital through Fifth Third Bank, drawing the full $25 million term loan and gaining access to a $10 million revolver. The term loan with Fifth Third Bank currently carries an interest rate of SOFR plus 2.25%. With that said, we made principal payments of $6.3 million in the third quarter. That number came in $6 million better than the payment timeline we'd laid out, which brought our outstanding debt to $13.4 million at September's close. Beyond that, once the quarter ended we paid down an additional $3 million in debt. Today our debt balance stands at $10.4 million. We intend to continue reducing principal on the outstanding loan faster than scheduled, even as we carry out our shared resources program. Bottom line results are still solid and align with our approach of generating sustainable, profitable growth. Turning now to KPIs for Q3 2026: average revenue per top 20 pharmaceutical manufacturer has reached $2.5 million. Net revenue retention came in at 83%, which is lower than what we saw in the prior period. The drop was driven mostly by a handful of large accounts trimming their spending rather than by churn across the board. On top of that, revenue per FTE stood at $706,000. While these KPIs are down compared with earlier quarters, we've made real strides on expanding margins and keeping operating expenses in check, and that fits with our strategy of pursuing profitable growth. Based on how we did through the first 9 months of 2026 and where we see the rest of the year heading, we're revising our guidance for 2026. We're looking for revenue to come in between $87 million and $93 million, and we're holding adjusted EBITDA at $21 million to $25 million. As Steve said, contracted revenue is still running about 20% under the same period a year ago, so a bigger chunk of revenue remains to be booked and recognized in the fourth quarter than we'd expected earlier. That does increase the execution risk around our revenue outlook, but we remain encouraged by a number of things: a customer that used to be significant is spending again, opportunities with key accounts are growing, there are signs of pent-up demand, and our new products and programmatic capabilities keep rolling out. We think those elements, along with the usual seasonal spending trends that come with Q4, provide a route toward hitting our goals for the entire year. Even so, how these opportunities land in terms of timing and conversion will be extremely important as we bring the year to a close. On profitability, our robust gross margins plus the gains from our cost-cutting efforts lend further backing to our adjusted EBITDA guidance. Before turning things over to Steve, I'd like to express my gratitude once more for all of your backing and confidence across the past 5 years. As I noted previously, I'm eager to stay involved with OptimizeRx's leadership team serving as a strategic advisor. I'd like to congratulate Andy and Heather once more on promotions they truly earned. Steve, the call is yours again.
Appreciate that, Ed. Operator, let's open it up for questions now. Our first caller is Ryan Daniels from William Blair. Go ahead.
Hi everyone, Dustin here. This is Ryan. Appreciate you taking our questions. It's really good to see the wins coming through with the programmatic partnerships. Now that you've got DeepIntent, The Trade Desk, and PulsePoint, I'm not sure whether you've roughly sized up what share of the programmatic space you've captured with those 3 DSPs combined, but maybe we could get a sense of how much runway remains. I know it's early innings, but just... my guess is there's plenty of runway, yet what percentage do these 3 account for together?
Thanks. Hey, Dustin. Appreciate the question. Good to hear your voice, and these 3 really are the 3 big ones in the space that we've pursued deliberately, with some intentionality. Our belief is they probably account for 60% to 70% of the volume in this space. So we're connected in the right spots. When it comes to generating revenue from the partners, still, as you pointed out, very, very early days. Building the swell on that will take a little while. But these integrations have already shown some really, I think, encouraging results in these early days for us when it comes to volume and bidding and acquisition. So we're feeling very good going into the '27 RFP season, as indicated in our sort of prepared remarks, and as is indicated in our contracted revenue running close to 20% ahead right now in RFP season. So looking strong on that; and a lot of it is due to some of the RFP stuff that's going through those programmatic desks; but we'll be able to size it more as we get up and running and start to see more flow; but these are the 3 big ones that we were targeting.
Understood. That's encouraging to hear. Could you perhaps discuss the movement you're making toward mid- and long-tail life science customers? Where do things stand on that, and how is it coming along?
Sure, glad to cover that. The mid-tier and long tail are showing extremely strong traction for us. We now have dedicated sales resources aimed at that segment. One mid-tier client entered our top 10 client pool during the last 2 quarters, which is very encouraging to see; and we've also seen really meaningful activity in the long tail, with clients buying 1 or 2 solutions, sort of testing things out. Still, those early signals give us considerable confidence in what we'll see from them in 2027. As was mentioned earlier on the call, part of the difficulty these mid-tier and long-tail clients face is that they lack the huge budgets needed to come in and spend on Salesforce resources and all the Cadillac benefits that the top 10 or 15 pharmaceutical manufacturers and agencies do. So our solutions essentially level the playing field for those mid-tier and long-tail clients. That's the reason we're starting to see outsized investment coming in from those portions of our client pool.
All right. Appreciate that; and only one more from us, NRR is probably not where you'd like it to be at present, having fallen to 83%. I'm just curious, is it fair to treat this as the trough quarter and expect improvement from here, or what's the right way to frame it going forward? Thanks.
Yeah, let me share a bit of perspective and then Ed and Andy will add their thoughts too. You know, I'd say much of the NRR and really the KPIs overall are heavily tied to the disruption at that 1 client and some of the pullback. I think once we normalize for '27, you're going to see those KPIs shift quite dramatically. So, one reason we're discussing what we're already seeing in 2027 is simply to help level set so people don't panic about the revenue model. Things actually look really, really good, but as we've committed as a leadership team before, we've been very effective at our guide. We wanted to be sure we were being transparent in our fourth quarter and given the lack of visibility in biops. We just didn't feel it would be fair to everybody to sort of roll the dice and try to hit it out of the park on biops when we may not get there simply without the visibility in Q4. So we're just over-communicating and making sure we're being clear, but we feel really great about '27; and that's really where the game is.
These figures, as you know, are oriented toward the last 12 months, but they're sort of fulfilling the purpose they were built for, which is to give you a feel for where the business stands given the trend currently established. Depending on how Q4 shakes out, I expect that number to begin improving as we head into '27.
Thanks, Ed. That was useful. I appreciate it a lot.
Now we'll take a question from Richard Baldry at Roth Capital Partners. Go ahead.
Thanks. Given how far along you are in RFP season right now, I'd like to know if you feel comfortable putting some sort of floor under '27 growth. Do you think you can get back to double-digit growth cleanly — low, mid, or double digit? Is there a way to frame what you've observed up to this point, and also that client of yours that was a headwind this year coming back?
Yeah, hey Rich, great to hear your voice. Looking forward to seeing you next week. Putting a floor out there isn't something we're ready to do. We haven't provided guidance for 2027 at this point, but as I mentioned, we're currently roughly 20% ahead on contracted revenue heading into '27. That gives us a solid signal for how we expect '27 to shape up. It's still early, of course, but the '27 projections resemble the growth rates from '25 more closely than those from '26. That's what we expected. When that client returned, we understood — given how large they are — that spending levels would begin to look more consistent and suitable relative to what we saw in '25. So it's too soon to issue guidance. RFP season feels quite strong. Our sales organization is performing really well, and the energy, overall mood, and culture inside the business are, I'd say, the strongest they've been in quite a while.
So let's set aside the drag from those top 20 accounts for a moment. Blended growth isn't as negative as the top 20, so can you talk about the health business outside the top 20? Is it growing well year over year? How are new logo wins trending? Perhaps in areas beyond pharma, such as biotech or med devices—or how do you view things outside that category as an indicator of underlying demand strength for what you offer?
Yes, I'd call the growth in the top 20 and the long tail very encouraging. So we're seeing a mix — not only pharma and biotech, but, as you mentioned, some MedTech players are coming in, along with other types of businesses that are leveraging our network and tools to take on bigger manufacturers. As I mentioned, one of those mid-tier clients did come to us — someone who's in the top 10, perhaps even top 5, in terms of status within the business this year and heading into next year. So that has us feeling quite encouraged, and we're seeing broader use cases for the platform and the technology — the way they're applying it is also widening the TAM for the business. So that's really positive. I’m not able to provide a separate growth figure, though I’d describe it as clearly in the double-digit range compared with where it stood a year ago. Andy and Ed, please jump in if there’s anything more you’d like to add—but overall, it’s very encouraging.
Yeah, I believe there's plenty of opportunity in the long tail; on the sales team we've got some really capable people who concentrate heavily on expanding it, and our view is that those budgets are available for us to capture.
Now, moving over to costs, would you say most of those efficiency improvements are already done? Are there additional places where you might apply AI technologies to push that further? And related to that, given how well EBITDA has held up, why concentrate on reducing debt so quickly rather than perhaps pursuing aggressive buybacks to reward your patient investors?
Sure, Andy, would you handle the EBITDA question, and Ed, could you address the debt reduction question?
Yes, we are always seeking ways to optimize our OpEx and our overall structure. Over the last 12 months, as you saw, we put into place a fairly significant cost-cutting strategy, and that is paying dividends to our bottom line right now. And as we go into 2027, we'll keep looking at that kind of stuff. Obviously, right now we're not going to commit to anything. But with AI continuing to advance and the automation initiatives we have within the company, we see a lot of opportunities. And, as we said before, we are looking to change that mix a little bit and actually start to push a little bit harder on the actual stock buyback. I would say stay tuned in Q4. I think you'll see more activity there from us on the equity buyback.
Understood. Thank you.
We now take a question from Josh Goldberg at B. Riley Securities. Go ahead.
Appreciate you fielding my question. It's encouraging to see yet another quarter with solid margins and debt reduction. I believe this point came up earlier, but 2027 contracted revenue appears to be moving in a positive direction. I'd like to dig a bit deeper into 4Q. I recall you said contracted revenue is running roughly 20% below prior levels. When I look at the implied guide for 4Q, it's approximately down 13% year-over-year. Is that gap genuinely a sound way to frame the potential risk at the midpoint overall, or how much of 4Q revenue, per the guidance, is already under contract as of today? Andy, would you like to handle that one?
Hi Josh, good to hear from you. At present, for the whole year, we need a bit above 90% in contracted revenue to reach the midpoint of our guidance range. In the two years before this one, we sat nearer the mid-90% mark, so there's a little more to secure this year. That said, clearly this year brought considerable disruption tied to that big customer, to MFN, and to items such as managed services; in cases like that, you'd usually expect somewhat more activity late in the fourth quarter. From what our sales team and sales-focused executives are telling us in their conversations, there appears to be sufficient pent-up demand to help close that gap.
Yeah, thank you for that detail, Andy. I remember in the past you mentioned that because of the company's big fixed cost base, roughly a 30% EBITDA margin is achievable. What I saw was that even though revenue declined, you posted a 29% EBITDA margin in this quarter; and since bookings appear fairly strong so far for 2027, do you figure that's a target you might potentially revisit, or could there be upside if the company returns to healthy double-digit growth?
Like Steve and I have said over the past few quarters, our operating model is genuinely scalable as the business keeps growing top-line; so our aim has always been to reach a 30% plus EBITDA margin as revenue keeps growing; now, we haven't finalized guidance or anything of that sort for 2027, so we won't commit to a 30% margin for next year, but clearly you can see a path exists to get there in the not-too-distant future.
That works for me. I appreciate it. Thank you.
<<operator_script>> We now take a question from Eric Martinuzzi at Lake Street Capital Markets. You may go ahead.
Yeah, I just wanted to get a better handle on this Q4 reset. Is that 20% below tracking figure something that's grown bigger as of this snapshot, or is it roughly where we stood coming out of Q1?
Hey Eric, appreciate the call. It's pretty much the same place we were. We haven't seen any improvement in contracted revenue year-over-year. We expected a bit more buy-up activity, and we simply haven't gotten the buy-up activity we were hoping for heading into the fourth quarter, as we've messaged and communicated very consistently throughout the year. We knew Q4 would hinge on some buy-ups returning, and we hoped we'd get our large disrupted client spending again and reengaged in the fourth quarter. I think we're delighted the client is back and spending. The levels remain small since they're beginning to invest from non-budgeted dollars, so they're returning on non-budgeted dollars, but they are spending, and I think in a fairly meaningful way. But visibility into buy-ups is the primary reason for the guidance adjustment. We just don't know at this point. There's a possibility we could see some of that come through, but we simply lack visibility. And I think we as a management team feel strongly that we want to keep being clear in our communication and try to manage expectations and preserve our credibility, which we've worked hard to build. So that's really the situation. And no major disruptions to contracted revenue. We just haven't yet seen the buy-up growth we're anticipating.
That does come across as odd, honestly. Pharma should be trying to bring customers in, in my view. You aren't a particularly large line item in their budget. So when I hear RFP momentum is up 20%, yet 2027 is up 20% while 2026 is down 20%, help me reconcile those figures.
Sure, contracted revenue gets tracked year-over-year as time goes on. So if you remove the $10 million plus tied to that 1 disrupted client and account for it, that accounts for a meaningful chunk of the 20% drop in contracted revenue year-to-date. So reaching that 20% doesn't require much; and then, if you think about how the RFP season and its output might shape up as we head into '27, that's where recovery begins to show. And that is in fact what we're seeing.
Yes, I'd agree with that. I mean, being 20% below with 3 quarters of the year now behind us is somewhat different from being 20% ahead with only a few weeks of our RFP season completed. As Steve mentioned, we're still in the early innings, but the signs are really positive that we're coming back strong in 2027. For this year, though, things are starting to get a bit baked in, and that's why our revenue expectations are down, consistent with what our backlog is showing us. Now, could Q4 bring an upside surprise? You never know. But the odds of that over the next 6 weeks are certainly getting somewhat lower than we'd like; so that's why we're dialing it down.
Now, Steve, with Congress flipping from Republican to Democrat, I realize that historically there are times when big pharma turns into a punching bag whenever that kind of party shift happens. I'm just curious whether your clients are expecting any of that as they look ahead to next year.
Yeah, we've had a couple of questions about that, or actually, I'd call them less questions and more remarks from clients on the subject. I think they're simply unsure, Eric. They're unsure. I think they've just been through what they expected would be a frothy stretch for them, given that the current administration is mostly Republican-controlled. And that wasn't the case, as we all know, they took a beating with the pinata stick through MFN and 5,000 other things. So what they figured would be a windfall for them under this administration and Congress and the House definitely was not. They've all readjusted their expectations on that. And so they truly don't know what to expect on this front; it's genuinely a fascinating topic. A few solid articles came out, I can go over them with you later, but there was 1 in Endpoints, another one in the Wall Street Journal, and I'd be glad to pass those along, along with some of the executives kind of sharing what they think; but we'll see how that develops.
Understood. Appreciate you taking my questions.
We now have David Grossman from Stifel on the line. Go ahead.
Thank you. In your prepared remarks, you said there are some encouraging signs of pent-up demand. Could you give us a bit more detail on what you're seeing and why it gives you encouragement?
Yeah, thanks David. Good to hear your voice, and I hope we'll see you soon. What we've observed is that throughout the year, people have warehoused dollars, waiting from Q1 through Q4 to see where they'll place bets and whether they'll get hit with this administrative pinata stick and have to course-correct. As I've already shared, we're seeing pockets of spend increase, especially in the mid-tier and long tail. And with several of the major brands we deal with, we believe that pent-up demand still exists. So we believe we'll begin to see some of the buy-up activity over the next 6 weeks. The challenge with recognizing the revenue is that we've got to contract it, deliver it, measure it, and so forth within a period of time, which is what Ed was articulating; and to accomplish all of that inside of 6 weeks at a broader level, we just want to make sure we're communicating clearly about it. As Ed said, the pent-up demand is there and it could materialize, but we don't have visibility into it. So we don't want to overpromise on that front, but it is there. And most of the time, as you know, David, from our conversations, these are use-it-or-lose-it dollars. So they're going to have to do something with the dollars they had warehoused for the first 3 quarters; we'll see how they deploy them.
Yeah, I wanted to build on what Steve said. If you look at the numbers, contracted revenue being up 20% year-over-year for that same period is a solid early signal of some demand that really wasn't showing up back in 2026.
One more point I want to make to you, David: if you look at a few of the other companies that have reported, the ones with a different revenue model that could be subscription in nature, their reported quarters are up for Q3 and the Q4 outlook; the main reason is that in their subscription-based models they're taking more of a forward-looking view. And that's a signal — I believe it's a bellwether of where the industry is trending. So if you'd like, we can discuss it further after the call.
Right, okay. No, thanks for that. And then just going back to what you said about the one big client that's pulled back this year. Based only on the figure you just gave us, is it fair to say that's roughly 10 points of NRR year-to-date, or for the year it'll come to about 10 points of NRR?
Yes, Ed, you can check that, or Andy.
That sounds about right. They accounted for 10% of customers last year, and during the first 9 months of this year, they generated no revenue at all.
Right, okay. So if I think about that — let's suppose the headwind mostly disappears, since you comp out and you're saying they'll begin growing a little, at least in terms of spending in the fourth quarter. Is there any reason to believe NRR wouldn't be 100 or better next year?
We haven't issued guidance yet. I wouldn't say we can truly give you that — I mean, that would be putting the cart before the horse when it comes to guidance. So obviously, if our business grows by a meaningful portion next year, NRR would rise above 100%. Historically, about 5% to 15% of our business has come from new logos each year; so if you sort of keep that in mind and apply whatever growth rate you consider reasonable for next year, you can more or less do a back-of-the-envelope calculation of what you'd expect NRR to be.
Yeah, I suppose the point I'm trying to make is whether we know of any other divots on the horizon that would hit '27?
No, nothing in '27. There is some '28 LOE that's coming, which we're preparing for and have already made plans around. You and I discussed that at our last conference. So it's just the usual course of business, but no big divots that we can see right now.
Cool. All right guys, good luck. Thank you.
That brings our question and answer session to an end. I'd now like to hand the floor back to Steve Silvestro for some closing remarks. Thank you, operator. And thanks to all of you for being with us on today's call. As we wrap up today's call, there are really 3 things I want us to keep our focus on. First, our third quarter results show the progress we've made in strengthening the financial foundation of OptimizeRx. Even though top-line growth for Q4 came in under what we had projected, the fact that we posted notably better adjusted EBITDA than anticipated shows what our margin improvement work, tight cost control, and the operating efficiencies put in place over the year have done for us. Those gains mean we're set up to drive more operating leverage once revenue growth picks back up, and I see that as really positive for everyone here. Next, we're convinced our technology platform is the strongest route to delivering performance — both the platform itself and our proprietary data set us apart in a meaningful way. The money we keep putting into our patent-protected DAP technology, the broader capabilities of NLAB, and our strategic tie-ups with programmatic DSPs like DeepIntent, The Trade Desk, and PulsePoint—along with ongoing product innovation—are opening fresh avenues for pharma manufacturers to reach healthcare providers and patients. Taken as a whole, these steps bolster where we stand competitively and widen our opportunities for growth over the long term. Third and finally, our attention stays fixed on turning these investments into stronger commercial execution. Although revenue from what we invested in 2026 has not yet been recorded, the demand signals coming from customers leave us highly encouraged. We're also feeling good about the strides our commercial team has made — it's brought fresh energy and strength to OptimizeRx's culture and to the opportunities tied to our growing product lineup. You can see those changes reflected in the contracted revenue growth we've booked so far this year for 2027, and that's a promising sign of what's coming. We think the progress achieved in 2026 has laid a sturdier groundwork for OptimizeRx's future, and we're still focused on sustainable growth, better profitability, and lasting value for our shareholders. Last, I want to thank our employees for their commitment and hard work, our customers and partners for continuing to place their trust in us, and our shareholders for their steady support. I want to give special thanks to Ed as well, for the advice, leadership, and stewardship he provided throughout his time at OptimizeRx, while he keeps handing things over to Andy and Heather and helping make sure we're ready for the company's next stage of growth. We're grateful you're with us today, and we look forward to bringing you up to date on how things go in the coming quarter.
Thanks, Mr. Silvestro. Before we close out today's call, I'd like to go over the company's safe harbor statement, which lays out the main cautions regarding the forward-looking statements we've made during this call. Comments from management on today's call could contain forward-looking statements as defined by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You shouldn't base investment decisions on forward-looking statements. Forward-looking statements are identified by terms like anticipate, believe, estimate, expect, intend, may, plan, possible, seeking, will, and similar expressions. Such statements speak only as of the date they are made. This call contains forward-looking statements, which cover several topics. They address our guidance for full-year 2026 revenue and adjusted EBITDA. They also touch on whether we can secure, convert, and recognize revenue in the fourth quarter. Other statements concern when customer spending will occur and return to normal, including anticipated pent-up demand and the 2027 RFP season, along with renewed spending from a customer that was significant in the past. The statements also cover expected gross margins for full-year 2026 and the advantages of our cost reduction and margin optimization efforts, plus the operating leverage those efforts should produce. They further address our commercial organization and go-to-market strategy, and our programmatic strategy and partnerships, including the anticipated availability of our inventory to PulsePoint advertisers. Additional statements concern the commercialization and adoption of our products and AI-enabled capabilities, including DAP, NLAB, and CoPayQ, as well as our competitive advantages and position. Finally, they address our capacity to generate recurring revenue opportunities and achieve sustainable long-term growth, our plan to repay outstanding debt ahead of schedule and possible share repurchases, the orderly transition of finance leadership responsibilities, and our ability to create long-term value for shareholders. Management’s outlook for the remainder of this year and for 2027 is likewise covered by forward-looking statements. There is no commitment by the company to publicly refresh or amend any forward-looking statement, whether as a result of fresh information, later events, or any other cause. Such statements carry inherent exposure to risks and uncertainties, and certain of these can be neither foreseen nor measured. What actually happens and what the company ultimately reports may diverge substantially from what these forward-looking statements state, envision, or imply. Forward-looking statements carry risks and uncertainties, among them when and how much customers spend, plus how well the company turns contracted and pipeline opportunities into recognized revenue. Other factors include government regulation and drug pricing policy, competition, reliance on a concentrated set of customers, how new products and programmatic partnerships perform, cybersecurity incidents that might disrupt operations, keeping up with technology that keeps growing and changing, sustaining contracts with electronic prescription platforms and electronic health records networks, risks tied to the company's indebtedness, and additional material risks. Risks and uncertainties to which forward-looking statements are exposed might influence the business and financial results; those are described in the company's annual report on Form 10-K for the year that ended December 31, 2025, as well as in subsequent quarterly reports on Form 10-Q and other documents the company has filed and may file with the SEC in the future. After such filings are made, they will be available on the company's website and also on the SEC's website at sec.gov. Before we wrap up today's conference, a quick reminder: an audio replay of this call will be posted this evening and will remain accessible for twelve months in the investor section of the company's website. Thanks to everyone. This live transcript is generated automatically, with no human involvement or review.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OptimizeRx Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to OptimizeRx Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.